TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25591431

Group type: EXPERIMENTAL
Intervention: PVI (pleth variability index) monitoring during passive leg raising (PLR) test
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SVV (stroke volume variation) monitoring during passive leg raising (PLR) test
Number of subjects: 87
Study: 23602769

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1391
Study: 20722026

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg twice daily
Number of subjects: 810

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: naproxcinod
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 810
Study: 18685062

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -15 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold pressor stress (CPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin supplementation
Number of subjects: 0
Study: 16779846

Group type: EXPERIMENTAL
Intervention: Bronchofiberscopes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bronchovideoscopes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of bronchofiberscopes and bronchovideoscopes
Number of subjects: 10
Study: 14673038

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen plus low-dose prednisone (p+T) for 12 months
Number of subjects: 320

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 320
Study: 10783220

Group type: EXPERIMENTAL
Intervention: Eptifibatide therapy
Number of subjects: 9461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9461
Study: 8836829

Group type: EXPERIMENTAL
Intervention: Information designed to increase anxiety about health
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Information designed to decrease anxiety about health
Number of subjects: 82
Study: 1460170

Group type: EXPERIMENTAL
Intervention: Global self‐ratings administered twice a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Itemized, prospective, observer‐rated scale administered twice a day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Retrospective item on the Hamilton Depression Rating Scale
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Atypical diurnal variation (mood worsening in the evening)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Typical diurnal variation (mood worsening in the morning)
Number of subjects: 37
Study: 30744529

Group type: EXPERIMENTAL
Intervention: AET+UC
Number of subjects: 57

Group type: COMPARATOR
Intervention: UC
Number of subjects: 57
Study: 27541314

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered maintenance intervention based on acceptance and commitment therapy (ACT)
Number of subjects: 48
Study: 27034176

Group type: EXPERIMENTAL
Intervention: Upfront EGFR‐TKI followed by SRS or WBRT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: WBRT then EGFR‐TKI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SRS followed by EGFR‐TKI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Upfront EGFR‐TKI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Upfront RT (WBRT or SRS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Upfront RT
Number of subjects: 50
Study: 25127659

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 220
Study: 22374684

Group type: EXPERIMENTAL
Intervention: THIN hospitalization documentation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: THIN-documented pneumonia admission
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: THIN hospitalization dates
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: THIN admission date
Number of subjects: 60
Study: 20204974

Group type: COMPARATOR
Intervention: CAD-only (n = 30)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CAD plus an additional four-session self-management group training (CAD+G, n = 31)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (waitlist, n = 30)
Number of subjects: 91
Study: 17397910

Group type: EXPERIMENTAL
Intervention: Cisplatin/paclitaxel or carboplatin/paclitaxel (exact dosage not specified)
Number of subjects: 761

Group type: COMPARATOR
Intervention: Surgery in centers with comprehensive surgical debulking including retroperitoneal lymphadenectomy and peritoneal stripping
Number of subjects: 761

Group type: COMPARATOR
Intervention: Higher pre-operative tumor load
Number of subjects: 761

Group type: COMPARATOR
Intervention: Higher FIGO stage
Number of subjects: 761

Group type: COMPARATOR
Intervention: Worse performance status
Number of subjects: 761

Group type: COMPARATOR
Intervention: Advanced age
Number of subjects: 761

Group type: COMPARATOR
Intervention: Presence of peritoneal carcinomatosis
Number of subjects: 761

Group type: COMPARATOR
Intervention: Post-operative residual tumor
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Aggressive primary surgery and complete debulking
Number of subjects: 761
Study: 15674097

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral esomeprazole 40 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 20 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral esomeprazole 20 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (both dosages)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral esomeprazole (both dosages)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both administration routes
Number of subjects: 64
Study: 12568187

Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open vertical banded gastroplasty (OVBG)
Number of subjects: 30
Study: 10450410

Group type: EXPERIMENTAL
Intervention: Questionnaire A
Number of subjects: 467

Group type: COMPARATOR
Intervention: Questionnaire B
Number of subjects: 467

Group type: COMPARATOR
Intervention: Dietary history interview
Number of subjects: 467
Study: 8576661

Group type: EXPERIMENTAL
Intervention: Furosemide 1 mg/kg immediate preoperation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no furosemide)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Furosemide group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 1970960

Group type: EXPERIMENTAL
Intervention: Plain tablets (500 mg theophylline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sustained-release formulation (500 mg theophylline)
Number of subjects: 6
Study: 394795

Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg qds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29165018

Group type: COMPARATOR
Intervention: Pedometer only (PED)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Individually tailored, Internet‐mediated pedometer (TI‐PED)
Number of subjects: 170
Study: 28887388

Group type: EXPERIMENTAL
Intervention: Minocycline 400 mg intravenous followed by 400 mg oral daily for 4 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 26513121

Group type: EXPERIMENTAL
Intervention: Allele variants of the serotonin transporter gene (5‐HTT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DNA methylation of the promoter region of the serotonin transporter gene
Number of subjects: 99
Study: 23692998

Group type: EXPERIMENTAL
Intervention: Spiders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-threatening objects (balls and ladybugs)
Number of subjects: 0
Study: 21458191

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily for 5 years
Number of subjects: 18348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18348

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 18348
Study: 19353539

Group type: EXPERIMENTAL
Intervention: 4 g fenugreek fiber
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 8 g fenugreek fiber
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 g fenugreek fiber (control)
Number of subjects: 18
Study: 17509194

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 179
Study: 14980901

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 micro g/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 100
Study: 11391747

Group type: EXPERIMENTAL
Intervention: Bromocriptine followed by bromocriptine + levodopa (group B/D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levodopa alone (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General French population
Number of subjects: 60
Study: 9246141

Group type: EXPERIMENTAL
Intervention: Hypertonic nebulised colistin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isotonic nebulised colistin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypotonic nebulised colistin
Number of subjects: 27
Study: 8516091

Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract (CLSE) administered at birth
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Early treatment (control group)
Number of subjects: 1248
Study: 3436153

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/amiloride (25 mg/2.5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/triamterene (25 mg/50 mg)
Number of subjects: 60
Study: 31706868

Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Pulmonary embolism
Number of subjects: 3000000
Study: 28918547

Group type: EXPERIMENTAL
Intervention: Adaptive step goal + reward intervention via smartphone app (Just Walk)
Number of subjects: 20
Study: 28969948

Group type: COMPARATOR
Intervention: Normal-weight patients (BMI ≤ 24.99)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 25-29.99)
Number of subjects: 256
Study: 26537944

Group type: EXPERIMENTAL
Intervention: 30 g pure whey protein isolate (L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 70 g pure whey protein isolate (H)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 23143590

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (3 × 1.5 h supervised sessions per week for 12 weeks)
Number of subjects: 41
Study: 21354547

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 80
Study: 18440484

Group type: EXPERIMENTAL
Intervention: Face-down position (P1 group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Seated position (P0 group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups (P0 and P1)
Number of subjects: 144
Study: 16563324

Group type: EXPERIMENTAL
Intervention: VIMA group (5% sevoflurane and 60% N2O in oxygen for induction; 2% sevoflurane and 60% N2O in oxygen for maintenance)
Number of subjects: 20

Group type: COMPARATOR
Intervention: TIVA group (propofol 2.0 mg/kg intravenously by bolus injection and fentanyl 2 microg/kg for induction; propofol 5 mg/kg per hour for maintenance)
Number of subjects: 20
Study: 14640847

Group type: EXPERIMENTAL
Intervention: Routine conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonroutine conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed participants (Study 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vacationers and kibbutz members (Studies 5 and 6)
Number of subjects: 0
Study: 11104482

Group type: EXPERIMENTAL
Intervention: Adjustable airbed
Number of subjects: 90

Group type: COMPARATOR
Intervention: Innerspring mattresses
Number of subjects: 90
Study: 9074373

Group type: EXPERIMENTAL
Intervention: Single catheter technique of hepatic venous isolation and charcoal hemoperfusion (HVI‐CHP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double‐balloon technique (group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single catheter technique (group B)
Number of subjects: 16
Study: 8457045

Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 20802

Group type: COMPARATOR
Intervention: Control group (no pulse oximetry monitoring)
Number of subjects: 20802
Study: 3520160

Group type: EXPERIMENTAL
Intervention: Infusion of glucose, insulin, and potassium
Number of subjects: 0
Study: 31036115

Group type: EXPERIMENTAL
Intervention: Unibody bifurcated endovascular stent-graft repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional open surgical repair
Number of subjects: 80
Study: 26830631

Group type: EXPERIMENTAL
Intervention: Church-based health-empowerment program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 70
Study: 26002004

Group type: EXPERIMENTAL
Intervention: Microincision (2.2 mm) phacoemulsification
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard (2.75 mm) phacoemulsification
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 23341572

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight loss (overall analysis)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unsupervised clustering
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 45
Study: 21884320

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 19302581

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 7.5 mg/month
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 11.25 mg every 3 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 22.5 mg every 3 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All groups (7.5 mg, 11.25 mg, 22.5 mg)
Number of subjects: 14
Study: 17352633

Group type: EXPERIMENTAL
Intervention: Laser needle acupuncture at Neiguan (PC6) with laser irradiation (36.8 kJ/cm(2))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group with no laser irradiation
Number of subjects: 45
Study: 15257847

Group type: EXPERIMENTAL
Intervention: Tailored follow-up intervention (mailed computer-tailored health messages and telephone counseling)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 511
Study: 11407567

Group type: EXPERIMENTAL
Intervention: Supported Conversation for Adults with Aphasia (SCA) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untrained volunteers)
Number of subjects: 40
Study: 9814458

Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 53
Study: 7711132

Group type: EXPERIMENTAL
Intervention: Penicillin + Metronidazole
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 76
Study: 2645824

Group type: EXPERIMENTAL
Intervention: Beta blockers (metoprolol and propranolol)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Follow-up (after washout)
Number of subjects: 58
Study: 788760

Group type: EXPERIMENTAL
Intervention: Brolitene (1200 mg per day, 6 tablets)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study: 30566641

Group type: EXPERIMENTAL
Intervention: Water supplementation (1.5 L daily for 6 weeks)
Number of subjects: 31
Study: 28660719

Group type: EXPERIMENTAL
Intervention: 16 phone-based lifestyle intervention sessions
Number of subjects: 200

Group type: COMPARATOR
Intervention: 16 educational mailings
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Participants not using insulin in the intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Participants not using insulin in the control group
Number of subjects: 200
Study: 25971243

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study: 22898451

Group type: EXPERIMENTAL
Intervention: Structured walking intervention (10-week program with pedometer-defined walks, fitness-tailored walking load)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Wait-list control condition (no intervention)
Number of subjects: 432
Study: 21470595

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 19466647

Group type: EXPERIMENTAL
Intervention: Go Sun Smart (GSS) campaign
Number of subjects: 0
Study: 18182864

Group type: EXPERIMENTAL
Intervention: Nurse presence program (experimental group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 39
Study: 15126990

Group type: EXPERIMENTAL
Intervention: Laronidase (100 U/kg, 0.58 mg/kg) administered intravenously weekly for 26 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo administered intravenously weekly for 26 weeks
Number of subjects: 45
Study: 11715612

Group type: EXPERIMENTAL
Intervention: Minimally invasive tracheostomy procedures
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Conventional operative tracheostomy
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Minimally invasive procedures
Number of subjects: 20000
Study: 9143566

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and chloramphenicol
Number of subjects: 114

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 114
Study: 7706587

Group type: COMPARATOR
Intervention: Isocal HN
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ultracal
Number of subjects: 10
Study: 3240302

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with 1 mmol NaH2PO4 per 100 ml
Number of subjects: 125

Group type: COMPARATOR
Intervention: Native human milk
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with NaH2PO4
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both feeding groups
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 125
Study: 31578760

Group type: EXPERIMENTAL
Intervention: Intervention effect estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard deviation estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability of non-compliance
Number of subjects: 0
Study: 28389125

Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet, statin and blood pressure lowering drugs
Number of subjects: 15140

Group type: EXPERIMENTAL
Intervention: Control in ≥four of five guideline levels of risk factors
Number of subjects: 15140

Group type: EXPERIMENTAL
Intervention: Prescription of BP-lowering drugs and statins at discharge
Number of subjects: 15140

Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 15140
Study: 25657051

Group type: EXPERIMENTAL
Intervention: Intensive individual counselling delivered by a practice nurse with 12 weeks of open-label varenicline
Number of subjects: 272

Group type: COMPARATOR
Intervention: Brief advice delivered by a general practitioner with 12 weeks of open-label varenicline
Number of subjects: 272
Study: 23856511

Group type: EXPERIMENTAL
Intervention: BUD/FORM 320/9 μg bid + TIO 18 μg qd
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: BUD/FORM + TIO
Number of subjects: 659

Group type: COMPARATOR
Intervention: PBO + TIO
Number of subjects: 659
Study: 21979186

Group type: EXPERIMENTAL
Intervention: Pedicle coagulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pedicle ligation
Number of subjects: 120
Study: 18667842

Group type: EXPERIMENTAL
Intervention: Topical methimazole 5% applied once daily for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical methimazole 5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral methimazole 5 mg tablet
Number of subjects: 20
Study: 19363280

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 20 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14766711

Group type: EXPERIMENTAL
Intervention: Urapidil 10-15 mg h(-1) continuous i.v. infusion for 3 days before surgery and until adrenal gland removal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 18
Study: 11332444

Group type: EXPERIMENTAL
Intervention: NIAAA screening strategy (combining alcohol consumption questions and CAGE questionnaire)
Number of subjects: 395
Study: 9387067

Group type: EXPERIMENTAL
Intervention: CABG with enoximone (used in all but 5 patients)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: CABG with intra-aortic balloon pump (used in 9 cases)
Number of subjects: 352
Study: 8189180

Group type: EXPERIMENTAL
Intervention: Computerised assessment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Human interviewer assessment
Number of subjects: 92
Study: 2888693

Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 20
Study: 31626100

Group type: EXPERIMENTAL
Intervention: Lidocaine (topical anesthesia of the throat and regional anesthesia of the scalp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia only (Control Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 0
Study: 28704847

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard postcesarean wound care (WC)
Number of subjects: 136
Study: 26142266

Group type: EXPERIMENTAL
Intervention: Drug therapy optimization
Number of subjects: 150
Study: 24443830

Group type: EXPERIMENTAL
Intervention: IDeg+Lira
Number of subjects: 177

Group type: COMPARATOR
Intervention: IDeg+IAsp
Number of subjects: 177